Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment

Article Clinical Neurology

COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders

Vanja Jovicevic et al.

Summary: This study investigated the demographic and clinical characteristics of NMOSD patients with COVID-19, as well as the safety data of COVID-19 vaccines in this population. The results showed overall favorable outcomes of COVID-19 in NMOSD patients and encouraging safety profile of the vaccines.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Rheumatology

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases

Cristiana Sieiro Santos et al.

Summary: Patients with IMRD receiving immunosuppressive therapies exhibit impaired immunogenicity after receiving mRNA SARS-CoV-2 vaccines, with drugs like methotrexate and azathioprine showing varying levels of impact on vaccine responses. Abatacept and B-cell depleting therapies have deleterious effects, while anticytokines help preserve immunogenicity. The effects of cumulative methotrexate and glucocorticoid doses on vaccine immunogenicity warrant consideration, and humoral and cellular responses show weak correlation while CD4 and CD8 responses are tightly correlated, suggesting a more nuanced evaluation than seroconversion alone.

RMD OPEN (2022)

添加到收藏夹

Article Clinical Neurology

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Celine Louapre et al.

Summary: SARS-CoV-2 antibody response was reduced in patients with MS or NMO-SD treated with anti-CD20 therapies, suggesting the need for long-term monitoring of reinfection risk and specific vaccination strategies in this population.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

添加到收藏夹

Article Clinical Neurology

Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies

Jelena Drulovic et al.

Summary: The study aimed to evaluate the humoral response to COVID-19 vaccines in patients with MS under high efficacy disease modifying therapies. Results showed that in some patients, seroprotection was achieved after vaccination despite the complex treatment circumstances.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Maria Pia Sormani et al.

Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.

EBIOMEDICINE (2021)

添加到收藏夹

Review Clinical Neurology